Table 1.

Number of Reported Novel Cellular Therapy Treatments in Europe in 2011 Sorted by Indication, Cell Source, and Donor Type

	Cell type and source
	Autologous					Allogeneic
Indication	HSC	MSC	Chondrocyte	Dermal fibroblast	Other	HSC	MSC	Keratinocyte	Other	Autologous	Allogeneic	Total
Cardiovascular
Peripheral artery disease	70	6								76	0	76
Cardiomyopathy	49	4								53	0	53
Heart failure	51									51	0	51
Myocardial ischemia	89	1			5					95	0	95
Bypass graft	9									9	0	9
Decubitus and leg ulcers		58								58	0	58
Other/unspecified	25	4			6					35	0	35
Musculoskeletal/rheumatological
Bone repair (maxillofacial)	19	5								24	0	24
Bone repair (orthopedics)	24	36								60	0	60
Osteogenesis imperfecta		2					2			2	2	4
Cartilage repair (orthopedics)		40	207							247	0	247
Muscle repair	9									9	0	9
Tendon/ligament		8								8	0	8
Reconstructive surgery/tissue enhancement		382	7		3					392	0	392
Scleroderma	4	3								7	0	7
Arthritis		38								38	0	38
Other/unspecified		12		1						13	0	13
Neurological
Multiple sclerosis	2	8				1	2			10	3	13
Parkinson's	1									1	0	1
Other/unspecified	19	4							4	23	4	27
Gastrointestinal
Crohn's disease		13					2			13	2	15
Liver insufficiency							4			0	4	4
Hematology/oncology
GvHD prevention or treatment						13	252			0	265	265
HSC graft enhancement	7	1					47			8	47	55
Miscellaneous
Skin reconstruction		29		36	0			31		65	31	96
Cornea repair					4					4	0	4
Diabetes									4	0	4	4
Solid tumor	10				28					38	0	38
Other	9	5		12	21		11			47	11	58
Total	397	659	214	49	67	14	320	31	8	1386	373	1759

HSC, hematopoietic stem cells; MSC, mesenchymal stromal/stem cells; GvHD, graft-versus-host disease.